A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Rilotumumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Amgen
- 21 Apr 2011 Status changed from active, no longer recruiting to discontinued.
- 23 Sep 2010 Planned end date changed from 1 Aug 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 26 Nov 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.